Sumit Parikh1, Amy Goldstein2, Mary Kay Koenig3, Fernando Scaglia4, Gregory M Enns5, Russell Saneto6,7, Irina Anselm8, Bruce H Cohen9, Marni J Falk10, Carol Greene11, Andrea L Gropman12, Richard Haas13, Michio Hirano14, Phil Morgan15, Katherine Sims16, Mark Tarnopolsky17, Johan L K Van Hove18, Lynne Wolfe19, Salvatore DiMauro14. 1. Department of Neurology, Center for Child Neurology, Cleveland Clinic Children's Hospital, Cleveland, Ohio, USA. 2. Department of Pediatrics, Division of Child Neurology, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA. 3. Department of Pediatrics, Division of Child and Adolescent Neurology, University of Texas Medical School at Houston, Houston, Texas, USA. 4. Department of Molecular and Human Genetics, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas, USA. 5. Department of Pediatrics, Division of Medical Genetics, Stanford University Lucile Packard Children's Hospital, Palo Alto, California, USA. 6. Department of Neurology, Seattle Children's Hospital, University of Washington, Seattle, Washington, USA. 7. Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, Washington, USA. 8. Department of Neurology, Boston Children's Hospital, Boston, Massachusetts, USA. 9. Department of Pediatrics, NeuroDevelopmental Science Center, Children's Hospital Medical Center of Akron, Akron, Ohio, USA. 10. Division of Human Genetics, Department of Pediatrics, The Children's Hospital of Philadelphia and University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA. 11. Department of Pediatrics, University of Maryland Medical Center, Baltimore, Maryland, USA. 12. Department of Neurology, Children's National Medical Center and the George Washington University of the Health Sciences, Washington, DC, USA. 13. Department of Neurosciences and Pediatrics, UCSD Medical Center and Rady Children's Hospital San Diego, La Jolla, California, USA. 14. Department of Neurology, Columbia University Medical Center, New York, New York, USA. 15. Department of Anesthesiology, Seattle Children's Hospital, Seattle, Washington, USA. 16. Department of Neurology, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts, USA. 17. Department of Pediatrics and Medicine, McMaster University, Hamilton, Ontario, Canada. 18. Department of Pediatrics, Clinical Genetics and Metabolism, Children's Hospital Colorado, Denver, Colorado, USA. 19. National Institutes of Health, Bethesda, Maryland, USA.
Abstract
PURPOSE: The purpose of this statement is to review the literature regarding mitochondrial disease and to provide recommendations for optimal diagnosis and treatment. This statement is intended for physicians who are engaged in diagnosing and treating these patients. METHODS: The Writing Group members were appointed by the Mitochondrial Medicine Society. The panel included members with expertise in several different areas. The panel members utilized a comprehensive review of the literature, surveys, and the Delphi method to reach consensus. We anticipate that this statement will need to be updated as the field continues to evolve. RESULTS: Consensus-based recommendations are provided for the diagnosis and treatment of mitochondrial disease. CONCLUSION: The Delphi process enabled the formation of consensus-based recommendations. We hope that these recommendations will help standardize the evaluation, diagnosis, and care of patients with suspected or demonstrated mitochondrial disease.
PURPOSE: The purpose of this statement is to review the literature regarding mitochondrial disease and to provide recommendations for optimal diagnosis and treatment. This statement is intended for physicians who are engaged in diagnosing and treating these patients. METHODS: The Writing Group members were appointed by the Mitochondrial Medicine Society. The panel included members with expertise in several different areas. The panel members utilized a comprehensive review of the literature, surveys, and the Delphi method to reach consensus. We anticipate that this statement will need to be updated as the field continues to evolve. RESULTS: Consensus-based recommendations are provided for the diagnosis and treatment of mitochondrial disease. CONCLUSION: The Delphi process enabled the formation of consensus-based recommendations. We hope that these recommendations will help standardize the evaluation, diagnosis, and care of patients with suspected or demonstrated mitochondrial disease.
Authors: Sarah E Calvo; Alison G Compton; Steven G Hershman; Sze Chern Lim; Daniel S Lieber; Elena J Tucker; Adrienne Laskowski; Caterina Garone; Shangtao Liu; David B Jaffe; John Christodoulou; Janice M Fletcher; Damien L Bruno; Jack Goldblatt; Salvatore Dimauro; David R Thorburn; Vamsi K Mootha Journal: Sci Transl Med Date: 2012-01-25 Impact factor: 17.956
Authors: Richard H Haas; Sumit Parikh; Marni J Falk; Russell P Saneto; Nicole I Wolf; Niklas Darin; Lee-Jun Wong; Bruce H Cohen; Robert K Naviaux Journal: Mol Genet Metab Date: 2008-02-01 Impact factor: 4.797
Authors: Debdeep Dutta; Lauren C Briere; Oguz Kanca; Paul C Marcogliese; Melissa A Walker; Frances A High; Adeline Vanderver; Joel Krier; Nikkola Carmichael; Christine Callahan; Ryan J Taft; Cas Simons; Guy Helman; Undiagnosed Diseases Network; Michael F Wangler; Shinya Yamamoto; David A Sweetser; Hugo J Bellen Journal: Hum Mol Genet Date: 2020-06-03 Impact factor: 6.150
Authors: Kathryn M Camp; Danuta Krotoski; Melissa A Parisi; Katrina A Gwinn; Bruce H Cohen; Christine S Cox; Gregory M Enns; Marni J Falk; Amy C Goldstein; Rashmi Gopal-Srivastava; Gráinne S Gorman; Stephen P Hersh; Michio Hirano; Freddie Ann Hoffman; Amel Karaa; Erin L MacLeod; Robert McFarland; Charles Mohan; Andrew E Mulberg; Joanne C Odenkirchen; Sumit Parikh; Patricia J Rutherford; Shawne K Suggs-Anderson; W H Wilson Tang; Jerry Vockley; Lynne A Wolfe; Steven Yannicelli; Philip E Yeske; Paul M Coates Journal: Mol Genet Metab Date: 2016-09-20 Impact factor: 4.797